Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)): The phase 2, multicenter N‐Road study

For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment, nilotinib achieved a higher rate of deep molecular response...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Nishiwaki, Kaichi, Sugimoto, Kei‐ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Tojo, Arinobu, Wakita, Hisashi
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286457/
https://ncbi.nlm.nih.gov/pubmed/32253827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3034
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares